Academic Journal
Q1Immuno-Oncology and Technology
About Immuno-Oncology and Technology
Immuno-Oncology and Technology is a scholarly journal published by Elsevier Inc.. SCImago 2025 lists it in Q1, with an SJR of 1.883 and H-index of 17.
Coverage: 2019-2026. Research categories: Immunology and Allergy (Q1); Oncology (Q1).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-04-27. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Cancer Immunotherapy and Biomarkers; Immunotherapy and Immune Responses; CAR-T cell therapy research; Lung Cancer Treatments and Mutations; Lung Cancer Research Studies; Cancer Genomics and Diagnostics.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Quality of life and care experience in durable responders to immune checkpoint inhibitors for advanced or metastatic NSCLC or melanoma
N. Girard, J. Bonastre, G. Spurrier, H. Lemasson et al.
2026-12 · DOI: 10.1016/j.iotech.2026.101613A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma
O. Kilim, O. Pipek, Z. Sztupinszki, M. Diossy et al.
2026-12 · DOI: 10.1016/j.iotech.2026.101614Age-related tumor mutational burden and inflammaging: a pan-cancer multi-omics study of treatment-naïve patients
S. Yajima, Y. Tsukada, Y. Sota, S.J.-Y. Ohtani-Kim et al.
2026-12 · DOI: 10.1016/j.iotech.2026.101616Why CD4+ T cells matter in adoptive cell therapy for solid cancers
S. Jegatheeson, C. Scheffler, M. De Bondt, P.K. Darcy et al.
2026-12 · DOI: 10.1016/j.iotech.2026.101615Corticosteroid exposure, tapering, and survival in immune-related colitis: a 10-year real-world melanoma cohort
S.K. Petersen, S. Madley, J. Kjeldsen, L. Bastholt et al.
2026-09 · DOI: 10.1016/j.iotech.2026.101610Germline BRCA1 pathogenic variants and T cell dysfunction
J. Kay, M.A. Harris, L.E. Lara Gonzalez, C.T. van Geelen et al.
2026-09 · DOI: 10.1016/j.iotech.2026.101601Reviving cancer vaccines in renal cell carcinoma: a new chapter in immunotherapy for kidney cancer
F.M. Scallo, J.J. Ishizuka, D.A. Braun
2026-09 · DOI: 10.1016/j.iotech.2026.101611Table of Contents
2026-09 · DOI: 10.1016/s2590-0188(26)00039-0Editorial Board
2026-09 · DOI: 10.1016/s2590-0188(26)00040-7Association between brown adipose tissue activity and clinical outcomes in melanoma: a retrospective PET/CT analysis
P. Toivanen, P. Ketonen, T. Vahlberg, K.A. Virtanen et al.
2026-09 · DOI: 10.1016/j.iotech.2026.101600Management of systemic lupus erythematosus and antiphospholipid syndrome during CAR-T therapy: insights from two clinical cases
C. Normand, S. Almaz, R. Stadelmann, M. Goodyer et al.
2026-09 · DOI: 10.1016/j.iotech.2026.101609Can mRNA vaccines ‘warm up’ cold tumours?
S. Copling, A. Grippin, S.H. Lin
2026-09 · DOI: 10.1016/j.iotech.2026.101596Motherhood’s immune legacy reshapes the breast for lasting cancer defence
P. Savas, B. Virassamy, M. Harris, S. Loi et al.
2026-09 · DOI: 10.1016/j.iotech.2026.101599Refuel and endure: improving metabolic fitness and efficacy in CAR-T therapy
I. Munoz, P.A. Beavis, P.K. Darcy, K. Sek et al.
2026-09 · DOI: 10.1016/j.iotech.2026.101583The effect of neoadjuvant radiotherapy on immune cell infiltrates in myxofibrosarcoma
M.J.L. Nederkoorn, U.E. Flucke, M.H.S. Hillebrandt-Roeffen, M.A.J. Gorris et al.
2026-06 · DOI: 10.1016/j.iotech.2026.101586Editorial Board
2026-06 · DOI: 10.1016/s2590-0188(26)00024-9Fresh-blood immune profiling of immune-related adverse events in real-world patients identifies organ-specific and steroid responsiveness signatures
M. Velasco Santiago, R.S. Jurlander, B. Albieri, I.M. Noringriis et al.
2026-06 · DOI: 10.1016/j.iotech.2026.101587Table of Contents
2026-06 · DOI: 10.1016/s2590-0188(26)00023-7Combining circulating inflammatory proteins and thymidine kinase activity to predict survival in melanoma patients receiving immune checkpoint inhibitors
S. Egyhazi Brage, F. Costa Svedman, M. Bergqvist, H. Helgadottir et al.
2026-06 · DOI: 10.1016/j.iotech.2026.101595The genome takes the wheel: CAR T with built-in circuits
K.M. Yap, P.K. Darcy, P.A. Beavis, A.X.Y. Chen et al.
2026-06 · DOI: 10.1016/j.iotech.2026.101597Reviews
Community Reviews
Version History
September 25, 2026 at 7:12 am
September 25, 2026